

ONE HUNDRED SIXTEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**  
COMMITTEE ON ENERGY AND COMMERCE  
2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115

Majority (202) 225-2927  
Minority (202) 225-3641

October 16, 2020

Helene Gayle, M.D., M.P.H.  
President & Chief Executive Officer  
The Chicago Community Trust  
225 N. Michigan Avenue, Suite 2200  
Chicago, IL 60601

Dear Dr. Gayle:

Thank you for appearing before the Subcommittee on Oversight and Investigations on Wednesday, September 30, 2020, at the virtual hearing entitled “Pathway to a Vaccine: Ensuring a Safe and Effective Vaccine People Will Trust.” We appreciate the time and effort you gave as a witness before the Subcommittee on Oversight and Investigations.

Pursuant to Rule 3 of the Committee on Energy and Commerce, members are permitted to submit additional questions to the witnesses for their responses, which will be included in the hearing record. Attached are questions directed to you from me and other members of the Committee. In preparing your answers to these questions, please address your responses to the member who has submitted the questions using the Word document provided with this letter.

To facilitate the publication of the hearing record, please submit your responses to these questions by no later than the close of business on Friday, October 30, 2020. As previously noted, your responses to the questions in this letter, as well as the responses from the other witnesses appearing at the hearing, will all be included in the hearing record. Your responses should be transmitted by email in the Word document provided with this letter to Benjamin Tabor with the Committee staff ([benjamin.tabor@mail.house.gov](mailto:benjamin.tabor@mail.house.gov)). A paper copy of your responses is not required. Using the Word document provided for submitting your responses will also help maintain the proper format for incorporating your answers into the hearing record.

Dr. Helene Gayle

Page 2

Thank you for your prompt attention to this request. If you need additional information or have other questions, please have your staff contact Mr. Tabor at (202) 225-2927.

Sincerely,

A handwritten signature in blue ink that reads "Frank Pallone, Jr." in a cursive style.

Frank Pallone, Jr.  
Chairman

Attachment

cc: Hon. Greg Walden, Ranking Member  
Committee on Energy and Commerce

Hon. Diana DeGette, Chair  
Subcommittee on Oversight and Investigations

Hon. Brett Guthrie, Ranking Member  
Subcommittee on Oversight and Investigations

**Committee on Energy and Commerce  
Subcommittee on Oversight and Investigations**

**Hearing on  
“Pathway to a Vaccine: Ensuring a Safe and Effective Vaccine People Will Trust”**

**September 30, 2020**

**Helene Gayle, M.D., M.P.H., President & Chief Executive Officer  
The Chicago Community Trust**

**The Honorable Frank Pallone, Jr. (D-NJ):**

1. How is the work of the National Academies of Sciences, Engineering, and Medicine’s (National Academies) Committee on Equitable Allocation of Vaccine for the Novel Coronavirus different than the traditional role in vaccine allocation by the Advisory Committee on Immunization Practices (ACIP)?
2. How is the National Academies’s Committee on Equitable Allocation of Vaccine for the Novel Coronavirus working with ACIP to ensure there is clear guidance on vaccine allocation once a vaccine is available?

**The Honorable Diana DeGette (D-CO):**

1. If any member of the Administration authorizes or approves the use of a coronavirus disease 2019 (COVID-19) vaccine prior to or over the objection of the U.S. Food and Drug Administration, or against the recommendations of the Vaccine and Related Biological Products Advisory Committee, what impact do you believe this action would have on the American people’s confidence in the vaccine?

**The Honorable Brett Guthrie (R-KY):**

1. Given that the vaccine supply schedule for H1N1 projected by manufacturers was much faster than what could actually be achieved, even for the initial supply target populations, how do you think ACIP and the Centers for Disease Control and Prevention (CDC) can reduce the possibility of unrealistic projections of the COVID-19 vaccine supply schedule?
2. The discussion draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine notes a major success from the H1N1 pandemic was the use of public-private partnerships to allocate and distribute the vaccine. What steps would you advise the CDC to take to ensure these types of partnerships are maximized so the COVID-19 vaccine can be distributed timely?

3. In addition to the extensive efforts to support development of vaccines and therapeutics themselves, the Administration has made efforts to secure ancillary supplies needed to administer vaccines—such as glass vials, needles, syringes, and alcohol pads. With the concern of medical supply chain shortages throughout this pandemic, how much emphasis was placed on ancillary supplies when creating the framework for distribution?